Quarta-Rad, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Quarta-Rad, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.21M | Apr 13, 2018 |
| FY2017 | Dec 31, 2016 | $826.8K | Apr 13, 2018 |
| FY2016 | Dec 31, 2015 | $829.0K | Apr 7, 2017 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.21M | Apr 13, 2018 |
| FY2017 | Dec 31, 2016 | $826.8K | Apr 13, 2018 |
| FY2016 | Dec 31, 2015 | $829.0K | Apr 7, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.6K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $39.7K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $183.4K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $396.7K | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $483.1K | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $212.9K | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $228.2K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $233.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $318.0K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $121.2K | Apr 13, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($256.9K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($216.8K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $44.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.6K | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $7.3K | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $75.5K | May 17, 2022 |
| FY2020 | Dec 31, 2019 | ($142.1K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($98.1K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $87.1K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($35.6K) | Apr 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($291.4K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($206.9K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($12.8K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $137.4K | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $120.8K | Jun 1, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $72.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $95.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $59.1K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.8K | Apr 13, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($75.1K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $49.8K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $200.0K | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $54.4K | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $36.5K | May 17, 2022 |
| FY2020 | Dec 31, 2019 | ($45.0K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $9.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.4K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($59.1K) | Apr 13, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $413.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $577.8K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $683.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $753.8K | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $581.6K | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $633.4K | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $244.9K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $274.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $279.9K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $202.3K | Apr 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $274.8K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $162.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $69.6K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $79.1K | Apr 13, 2018 |
| FY2016 | Dec 31, 2015 | $129.3K | Apr 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $176.8K | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $393.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $349.1K | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $334.5K | Aug 16, 2024 |
| FY2022 | Dec 31, 2020 | $318.2K | Jun 1, 2023 |
| FY2021 | Dec 31, 2019 | ($29.8K) | May 17, 2022 |
| FY2020 | Dec 31, 2018 | $112.2K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $210.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $123.2K | Apr 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($428.4K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($171.5K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $45.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $807 | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | ($13.8K) | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | ($21.1K) | May 17, 2022 |
| FY2020 | Dec 31, 2019 | ($96.6K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $45.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $143.5K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $56.4K | Apr 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.9K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $63.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $72.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $293.9K | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | $260.2K | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | $108.1K | May 17, 2022 |
| FY2020 | Dec 31, 2019 | $42.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $87.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $77.9K | Apr 15, 2019 |
| FY2018 | Dec 31, 2016 | $67.5K | Apr 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.90M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 15.67M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 15.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 15.67M | Aug 16, 2024 |
| FY2022 | Dec 31, 2021 | 15.67M | Jun 1, 2023 |
| FY2021 | Dec 31, 2020 | 15.66M | May 17, 2022 |
| FY2020 | Dec 31, 2019 | 15.33M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 15.33M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 15.33M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 15.33M | Apr 13, 2018 |